# OnCo record c2i-genomics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/c2i-genomics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "c2i-genomics" ;
  schema:name "C2i Genomics"@en ;
  schema:description "C2i Genomics built a blood test that reads the whole genome of tumour DNA fragments to detect leftover cancer after treatment; Veracyte bought the company in 2024 and now sells the approach as TrueMRD."@en ;
  schema:url <https://onco.cc/companies/c2i-genomics/>, <https://www.veracyte.com/innovation/truemrd-platform/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.veracyte.com/innovation/truemrd-platform/>, <https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036dex991.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/wes-wgs/> .